ANI Pharmaceuticals, Inc. ANIP R2K
Healthcare · Drug Manufacturers - Specialty & Generic · United States
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
READ MORE ›$78.51
+33.70% 1Y
Market & Price
Market Cap
$1.78B
Current Price
$78.51
High / Low (52W)
$98.81 / $58.72
Beta
0.46
Valuation
Stock P/E
20.08
Industry PE
23.65
Forward P/E
7.40
PEG Ratio
-
Book Value
$26.34
Price to Book
2.98
P/S
1.93
EV/EBITDA
9.97
Dividend Yield
-
Profitability & Returns
ROCE
9.97%
ROE
18.32%
ROA
4.97%
Profit Margin
9.98%
Op Margin
16.30%
EPS (Latest Qtr)
$1.28
EPS (TTM)
$3.91
Balance Sheet & Liquidity
Debt/Equity
1.12
Quick Ratio
2.43
Current Ratio
3.12
Debt
$630.21M
Total Assets
$1.44B
Current Assets
$753.12M
Working Capital
$475.00M
Ownership
Promoter Holding
6.89%
Chg in Prom Hold
-0.48%
FII / Inst Holding
110.26%
Chg in FII Hold
0.00%
Financial Snapshot
Enterprise Value
$1.97B
Total Revenue (TTM)
$923.71M
EBITDA
$197.38M
Free Cash Flow
$140.26M
Operating Cash Flow
$208.61M
Shares Outstanding
22.73M
Gross Margin
60.83%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
40.81%
Profit 5Y
87.85%
Revenue (YoY)
20.50%
Earnings (YoY)
86.10%
PROS
- Compounding revenue at 40.8% over 5 years.
- Profit CAGR of 87.9% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ANIP ANI Pharmaceuticals, Inc. R2K | 78.51 | 20.08 | $1.78B | - | 9.97% | 18.32% | 40.81% | 87.85% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 36.63M | 44.76M | 48.16M | - | 46.48M | 47.27M | 50.70M | - | 52.89M | 54.36M | 51.34M | 47.97M | 49.77M | 48.47M | 52.98M | 57.25M | 54.52M | 48.62M | 52.06M | 64.48M | 73.86M | 83.82M | 106.79M | 116.55M | 131.83M | 137.43M | 138.04M | - | - | 197.12M | 211.37M | 227.81M | 247.06M | 237.46M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 73.04M | 74.61M | 93.39M | 100.27M | 93.58M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 124.08M | 136.76M | 134.42M | 146.79M | 143.88M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 109.98M | 121.59M | 111.59M | 117.66M | 105.17M |
| Operating Income | 8.45M | 6.27M | 5.67M | 5.19M | 7.92M | 1.30M | 4.62M | 6.99M | 9.33M | 7.38M | 6.54M | 7.26M | 10.11M | 11.45M | 4.40M | 9.29M | 7.33M | -4.67M | -7.84M | -11.31M | 2.80M | 331.00K | 3.04M | -15.55M | -3.56M | -19.20M | -12.91M | -5.00M | 9.89M | 12.40M | 17.95M | 20.31M | 5.17M | - | - | 14.10M | 15.17M | 22.83M | 29.13M | 38.71M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 48.36M | 39.24M | 61.16M | 58.50M | 64.91M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.48M | 5.44M | 4.73M | 4.41M | 3.77M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.99M | 10.53M | 33.80M | 31.48M | 40.22M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.31M | 1.98M | 7.18M | 3.99M | 10.73M |
| Net Income | 4.56M | - | 1.35M | 1.12M | 2.54M | - | 1.15M | 2.68M | 4.72M | - | 2.25M | 2.78M | 5.04M | - | 449.00K | 6.58M | 3.90M | -4.83M | -7.01M | -12.34M | 434.00K | -3.63M | 86.00K | -14.11M | -4.45M | -20.13M | -14.92M | -8.60M | 1.44M | 6.25M | 9.94M | 18.21M | -2.29M | - | - | 15.68M | 8.55M | 26.62M | 27.49M | 29.49M |
| Diluted EPS | 0.39 | 0.25 | 0.12 | 0.10 | 0.22 | -0.09 | 0.10 | 0.23 | 0.40 | -0.83 | 0.19 | 0.23 | 0.42 | 0.46 | 0.04 | 0.53 | 0.32 | -0.41 | -0.59 | -1.03 | 0.04 | -0.30 | 0.01 | -1.17 | -0.37 | -1.27 | -0.94 | -0.55 | 0.06 | 0.29 | 0.45 | 0.82 | -0.14 | - | - | 0.69 | 0.36 | 1.13 | 1.18 | 1.28 |
| R&D Expense | 815.00K | - | 966.00K | 764.00K | 1.04M | - | 1.62M | 2.17M | 2.63M | - | 2.10M | 5.14M | 4.67M | - | 4.37M | 5.77M | 4.98M | - | 6.34M | 3.04M | 2.94M | - | 2.97M | 2.81M | 2.46M | 5.27M | 4.17M | 7.66M | 5.92M | 7.37M | 11.12M | 10.51M | 7.30M | 10.13M | - | 10.56M | 16.54M | 12.30M | - | 10.60M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 128.62M | 176.84M | 201.58M | 206.55M | 208.47M | - | 316.38M | 486.82M | 614.38M | 883.37M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 138.78M | 181.51M | 250.21M | 341.31M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | 177.60M | 305.30M | 364.17M | 542.06M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 203.33M | 255.77M | 361.95M | 460.83M |
| Operating Income | - | - | - | -42.00K | 898.00K | 20.01M | 32.70M | 20.08M | 28.33M | 35.36M | 16.35M | -16.02M | - | -25.73M | 49.53M | 2.22M | 81.23M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 25.04M | 106.60M | 63.12M | 207.27M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.05M | 26.94M | 17.60M | 20.06M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -62.66M | 19.87M | -22.21M | 95.79M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.77M | 1.09M | -3.69M | 17.45M |
| Net Income | - | - | - | -1.51M | 301.00K | 28.75M | 15.38M | 3.93M | -1.08M | 15.49M | 6.09M | -22.55M | - | -47.90M | 18.78M | -18.52M | 78.34M |
| Diluted EPS | -1.40 | -4.21 | -3.15 | -1.27 | -0.92 | 2.59 | 1.32 | 0.34 | -0.09 | 1.30 | 0.50 | -1.88 | - | -3.05 | 0.85 | -1.04 | 3.32 |
| R&D Expense | 13.68M | 39.71M | 44.18M | 1.16M | 1.71M | 2.68M | 2.87M | 2.91M | 9.07M | 15.39M | 19.81M | 16.00M | 11.37M | 22.32M | 34.29M | 44.58M | 51.66M |
Compounded Sales Growth
| 5 Years: | 40.81% |
| 1 Year: | 20.50% |
Compounded Profit Growth
| 5 Years: | 87.85% |
| 1 Year: | 86.10% |
Stock Price Performance
| 1 Year: | +33.70% |
| 6 Months: | -5.66% |
| 3 Months: | +6.24% |
| 1 Month: | +0.69% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 44.77M | 62.38M | 13.75M | 44.50M | 259.56M | 285.26M | 322.86M | 412.14M | 430.60M | 456.79M | 461.19M | - | 760.09M | 904.42M | 1.28B | 1.44B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 344.26M | 519.82M | 528.46M | 753.12M |
| Cash & Equivalents | 11.76M | 29.86M | 38.16M | 0 | 11.00K | 11.11M | 169.04M | 154.68M | 27.36M | 31.14M | 43.01M | 62.33M | 7.86M | - | 48.23M | 221.12M | 144.86M | 285.58M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 105.36M | 111.20M | 136.78M | 143.07M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 165.44M | 162.08M | 221.73M | 281.08M |
| Total Liabilities | - | - | 25.62M | 24.56M | 10.59M | 3.54M | 119.77M | 125.18M | 153.22M | 237.38M | 233.34M | 244.00M | 265.49M | - | 421.55M | 446.82M | 855.94M | 899.65M |
| Current Liabilities | - | - | 8.18M | 7.23M | 7.71M | 3.54M | 13.23M | 11.76M | 31.95M | 39.23M | 165.55M | 61.68M | 78.56M | - | 99.44M | 145.48M | 194.45M | 278.11M |
| Long Term Debt | - | - | - | - | - | - | - | - | 0 | 69.95M | 67.30M | 175.81M | 172.44M | - | 285.67M | 284.82M | 614.92M | 599.77M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 286.52M | 285.67M | 624.09M | 617.03M |
| Total Equity | 13.83M | 15.83M | 19.15M | -34.28M | -42.72M | 40.96M | 139.78M | 160.08M | 169.65M | 174.76M | 197.26M | 212.79M | 195.70M | - | 338.54M | 457.60M | 428.53M | 540.72M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.64M | 20.73M | 21.54M | 23.11M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -137.00K | -5.48M | 22.03M | 17.26M | 27.47M | 39.42M | 67.07M | 45.63M | 15.27M | - | -31.20M | 118.96M | 64.02M | 185.22M |
| Investing Cash Flow | - | - | - | - | - | -35.75M | -32.68M | -149.06M | -107.99M | -27.38M | -27.55M | -68.32M | - | -15.74M | -18.51M | -404.72M | -34.32M |
| Financing Cash Flow | - | - | - | 440.00K | -3.69M | 171.65M | 1.07M | -729.00K | 72.36M | -27.82M | 1.25M | -1.44M | - | -5.13M | 67.44M | 264.94M | -9.94M |
| Capital Expenditure | -165.72K | -63.44K | -719.92K | -292.00K | -191.00K | -1.12M | -2.18M | -4.57M | -10.37M | -5.74M | -6.63M | -6.13M | - | -16.45M | -18.51M | -16.95M | -34.32M |
| Free Cash Flow | - | - | - | -429.00K | -5.67M | 20.91M | 15.08M | 22.91M | 29.05M | 61.33M | 39.00M | 9.13M | - | -47.66M | 100.45M | 47.06M | 150.90M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -52.07M | 167.89M | -75.76M | 140.96M |
| Share Buybacks | - | - | - | 0 | 433.00K | 0 | 0 | 2.50M | 0 | 0 | 1.03M | 1.52M | 890.00K | 1.96M | 4.99M | 10.96M | 12.21M |
| Dividends Paid | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 190.00K | 1.62M | 1.62M | 1.62M | 1.16M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | 56.1% | 62.7% | 59.3% | 61.4% |
| Operating Margin % | - | - | - | - | - | - | - | 15.6% | 16.0% | 17.5% | 7.9% | -7.7% | - | -8.1% | 10.2% | 0.4% | 9.2% |
| Net Margin % | - | - | - | - | - | - | - | 3.1% | -0.6% | 7.7% | 3.0% | -10.8% | - | -15.1% | 3.9% | -3.0% | 8.9% |
| ROE % | - | - | - | 3.5% | 0.7% | 20.6% | 9.6% | 2.3% | -0.6% | 7.9% | 2.9% | -11.5% | - | -14.1% | 4.1% | -4.3% | 14.5% |
| ROCE % | - | - | - | -0.7% | 2.2% | 8.1% | 12.0% | 6.9% | 7.6% | 13.3% | 4.1% | -4.2% | - | -3.9% | 6.5% | 0.2% | 7.0% |
Shareholding Pattern
Insiders
6.89%
Institutions
110.26%
Public Float
118.42%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 12.09% | 2.75M | $215.71M |
| 2 | Vanguard Capital Management LLC | 3.62% | 823.06K | $64.62M |
| 3 | Soleus Capital Management, L.P. | 3.61% | 820.24K | $64.40M |
| 4 | State Street Corporation | 3.39% | 771.59K | $60.58M |
| 5 | Tang Capital Management, LLC | 3.11% | 707.50K | $55.55M |
| 6 | Goldentree Asset Management LP | 2.94% | 667.98K | $52.44M |
| 7 | Deep Track Capital, Lp | 2.64% | 600.00K | $47.11M |
| 8 | Millennium Management Llc | 2.60% | 592.01K | $46.48M |
| 9 | Arrowstreet Capital, Limited Partnership | 2.48% | 564.36K | $44.31M |
| 10 | Dimensional Fund Advisors LP | 2.34% | 531.19K | $41.70M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ANIP
No recent headlines available.